CRISPR Therapeutics AG Quarterly Income Tax Expense (Benefit) in USD from Q3 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
CRISPR Therapeutics AG quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q3 2015 to Q3 2024.
  • CRISPR Therapeutics AG Income Tax Expense (Benefit) for the quarter ending September 30, 2024 was $876K, a 113% increase year-over-year.
  • CRISPR Therapeutics AG Income Tax Expense (Benefit) for the twelve months ending September 30, 2024 was $3.12M.
  • CRISPR Therapeutics AG annual Income Tax Expense (Benefit) for 2023 was $2.89M.
  • CRISPR Therapeutics AG annual Income Tax Expense (Benefit) for 2022 was -$325K, a 117% decline from 2021.
  • CRISPR Therapeutics AG annual Income Tax Expense (Benefit) for 2021 was $1.87M, a 131% increase from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $3.12M $876K +$464K +113% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-05
Q2 2024 $2.66M $1.29M +$364K +39.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-05
Q1 2024 $2.29M $724K -$596K -45.2% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $2.89M $233K +$9.71M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-21
Q3 2023 -$6.82M $412K +$987K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 -$7.81M $923K -$5.2M -84.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 -$2.61M $1.32M -$2.29M -63.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$325K -$9.48M -$7.22M -321% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-21
Q3 2022 $6.9M -$575K +$20K +3.36% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $6.88M $6.12M +$1.98M +47.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $4.9M $3.61M +$3.03M +527% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $1.87M -$2.25M -$2.11M -1433% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $3.98M -$595K -$795K -398% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $4.77M $4.14M +$3.76M +993% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $1.01M $575K +$198K +52.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $809K -$147K -$151K -3775% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $960K $200K -$74K -27% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $1.03M $379K +$294K +346% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $740K $377K +$292K +344% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 $448K $4K -$230K -98.3% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 $678K $274K +$137K +100% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 $541K $85K -$11K -11.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-27
Q1 2019 $552K $85K -$1K -1.16% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q4 2018 $553K $234K -$186K -44.3% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-16
Q3 2018 $739K $137K -$570K -80.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-28
Q2 2018 $1.31M $96K -$247K -72% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-29
Q1 2018 $1.56M $86K -$193K -69.2% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 $1.75M $420K +$20K +5% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-12
Q3 2017 $1.73M $707K +$699K +8738% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $1.03M $343K +$343K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $687K $279K +$203K +267% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $484K $400K Oct 1, 2016 Dec 31, 2016 10-K 2019-02-25
Q3 2016 $8K -$145K -94.8% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $0 Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 $76K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q3 2015 $153K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.